Trial reportBMC ophthalmology2025
Comparison of the influence of 1% and 0.01% atropine on the corneal topography in myopic children.
Trial report in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03949101 (Atropine for Children and Adolescent Myopia Progression Study), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Atropine for Children and Adolescent Myopia Progression Study (ACAMP)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the alterations in corneal topography with either 1% or 0.01% atropine treatment in myopic children.
methodsThis 6-month randomized controlled trial enrolled myopic children aged 6-12 years and randomly allocated them to group A (n = 92; 1% atropine once weekly) or group B (n = 85; 0.01% atropine once daily). Scheimpflug imaging was performed at baseline, 1 week, 3 months, and 6 months post-administration.
resultsIn group A, a significant hyperopic shift (0.29 D) and progression of cylinder refraction (-0.10 D) were occurred. This cylindrical change exhibited a positive correlation with posterior corneal astigmatism. In group B, myopia progression was observed (-0.25 D), but the cylinder refraction changes were not significant (-0.04 D). A significant reduction in anterior keratometry (-0.08 D) and a concomitant increase in posterior corneal astigmatism (0.04 D) were documented. Furthermore, cylindrical change exhibited inverse associations with younger age, spherical refraction, and posterior corneal astigmatism. Changes in posterior corneal asphericity (Q-value) were inversely correlated with spherical refraction. Moreover, both groups exhibited significant posterior Q-value flattening (-0.13 and - 0.15, respectively), and changes in posterior K1 and K2 were positively correlated with the Q-value change.
conclusionWe found that 1% or 0.01% atropine had a minor impact on the corneal topography. Longitudinal alterations in corneal geometry are predominantly ascribable to physiological ocular growth and myopic progression rather than to atropine exposure. TRIAL REGISTRATION NUMBER: Clinical Trials.gov PRS (Registration No. NCT03949101). Registration Date: 2019-05-11.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.